Total Valuation
Sinopharm Group Co has a market cap or net worth of €5.18B. The enterprise value is €23.42K.
Market Cap€5.18B
Enterprise Value€23.42K
Share Statistics
Sinopharm Group Co has 268,362,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding268,362,150
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sinopharm Group Co’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 5.69%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)5.69%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee5.90M
Profits Per Employee155.93K
Employee Count94,910
Asset Turnover1.43
Inventory Turnover8.19
Valuation Ratios
The current PE Ratio of Sinopharm Group Co is 5.6. Sinopharm Group Co’s PEG ratio is -4.41.
PE Ratio5.6
PS Ratio0.10
PB Ratio0.64
Price to Fair Value0.64
Price to FCF4.32
Price to Operating Cash Flow1.97
PEG Ratio-4.41
Income Statement
In the last 12 months, Sinopharm Group Co had revenue of 559.50B and earned 6.96B in profits. Earnings per share was 11.10.
Revenue559.50B
Gross Profit40.09B
Operating Income16.21B
Pretax Income14.40B
Net Income6.96B
EBITDA20.38B
Earnings Per Share (EPS)11.10
Cash Flow
In the last 12 months, operating cash flow was 22.20B and capital expenditures -1.53B, giving a free cash flow of 20.67B billion.
Operating Cash Flow22.20B
Free Cash Flow20.67B
Free Cash Flow per Share77.02
Dividends & Yields
Sinopharm Group Co pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change-12.57%
50-Day Moving Average8.84
200-Day Moving Average9.83
Relative Strength Index (RSI)40.33
Average Volume (3m)2.00
Important Dates
Sinopharm Group Co upcoming earnings date is Nov 2, 2026, TBA (Not Confirmed).
Last Earnings DateAug 23, 2026
Next Earnings DateNov 2, 2026
Ex-Dividend Date―
Financial Position
Sinopharm Group Co as a current ratio of 1.41, with Debt / Equity ratio of 133.57%
Current Ratio1.41
Quick Ratio1.15
Debt to Market Cap1.24
Net Debt to EBITDA2.31
Interest Coverage Ratio6.68
Taxes
In the past 12 months, Sinopharm Group Co has paid 3.86B in taxes.
Income Tax3.86B
Effective Tax Rate0.27
Enterprise Valuation
Sinopharm Group Co EV to EBITDA ratio is 4.96, with an EV/FCF ratio of 8.08.
EV to Sales0.18
EV to EBITDA4.96
EV to Free Cash Flow8.08
EV to Operating Cash Flow7.16
Balance Sheet
Sinopharm Group Co has €41.90B in cash and marketable securities with €113.83B in debt, giving a net cash position of -€71.93B billion.
Cash & Marketable Securities€41.90B
Total Debt€113.83B
Net Cash-€71.93B
Net Cash Per Share-€268.05
Tangible Book Value Per Share€198.84
Margins
Gross margin is 7.03%, with operating margin of 2.90%, and net profit margin of 1.24%.
Gross Margin7.03%
Operating Margin2.90%
Pretax Margin2.57%
Net Profit Margin1.24%
EBITDA Margin3.64%
EBIT Margin2.90%
Analyst Forecast
The average price target for Sinopharm Group Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-4.46%
EPS Growth Forecast0.14%